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Abstract: Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite
continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human
transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously
thought and the lack of dialogue between researchers and industrials and consensus on guidelines to
generate data make it harder to compare and reproduce results. This European Cooperation in Science
and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and
further the translation of experimental data into usable applications to improve personalized medicine
in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration
between stakeholders from complementary backgrounds, allowing the functions of different RNAs
and their interactions to be more rapidly deciphered in the cardiovascular context for translation
into the clinic, thus fostering personalized medicine and meeting a current public health challenge.
Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative
projects, and consolidate the leadership of European research groups in the field. COST (European
Cooperation in Science and Technology) is a funding organization for research and innovation
networks (www.cost.eu).
Keywords: cardiovascular disease; transcriptomics; best practices and guidelines; translational
research; personalized medicine
1. Introduction
Cardiovascular diseases (CVD) remain the main cause of death worldwide despite technological
and medical advances and is responsible for debilitating a significant number of patients annually.
To discover novel diagnostic and prognostic tools and develop new treatments, understanding the
molecular mechanisms in a comprehensive view is essential. Such knowledge can forward personalized
medicine, where interventions are tailored to the individual patient, potentially improving the lives of
millions of people, and reducing healthcare costs.
One way to promote this area is by studying the transcriptome, which is the set of all different types
of RNA produced in a cell and that may be involved in the pathogenesis of several diseases, including
cardiovascular ones. However, the human transcriptome is much more complex and challenging to
study than previously thought, and new types of RNA are frequently revealed. Currently, there are
relatively isolated research groups working on the same subject and sometimes using different standards
to generate data, making it harder to compare and reproduce results. This is particularly true when
aiming to develop products for personalized medicine because they must deliver accurate information
and high reproducibility.
This European Cooperation in Science and Technology (COST) Action will provide a platform to
coordinate the efforts of different groups and offer opportunities for collaboration between clinicians
and scientists from interdisciplinary backgrounds to more rapidly decipher the role of different forms
of RNA in CVD and allow for the transfer of such knowledge into practical applications for diagnostics
and therapies. CardioRNA members aim to refine and implement guidelines for transcriptomic
studies in CVD, tackling the whole investigation pipeline to improve comparison between studies from
different laboratories and reproducibility of results, allowing faster development of new RNA-based
tools for personalized medicine. This Action also aims to enable enhancement and continuity of the
network efforts in improving the understanding of the transcriptome in the cardiovascular context and
advancement of personalized medicine. Finally, it has the goal to provide a platform to train the next
generation of researchers and students in the field.
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2. Relevance and Timeliness
Non-communicable diseases are the major global disease burden, with CVD as the leading cause
of death, accounting for 17.5 million deaths per year, a number that is estimated to increase [1].
The socioeconomic burden of CVD due to premature deaths and reduced quality of life is substantial.
It has been estimated to cost €210 billion annually to the European Union alone [2]. Considerable
parts of the world are at significant risk for CVD, which, as a chronic disease, may be caused by
cumulative biological, behavioral, and social risks. Nonetheless, the main risk factors contributing
to CVD tend to be consistent worldwide: Hypertension, diabetes, poor diet and obesity, physical
inactivity, and smoking [3].
The modern lifestyle that promotes sedentary behavior and ingestion of high-calorie foods has
resulted in an obesity epidemic around the globe and is related to the increasing incidence of chronic
diseases, particularly cardiovascular ones [4]. Such aspects of modern lifestyle result in abnormal
gene expression, contributing to the development of pathologies that significantly increase the risk for
CVD development, such as obesity, atherosclerosis, type 2 diabetes, and hypertension. The high and
increasing prevalence of these chronic conditions has contributed to the pandemic of CVD [5].
Environmental factors, such as those mentioned above, can affect gene expression, which is
reflected by the transcriptome. For many years, there was an emphasis on the study of protein-coding
genes giving rise to messenger RNA (mRNA). More recently, the emergence of non-coding RNA genes
(ncRNA) has allowed the scientific community to appreciate the full complexity of the transcriptome.
The discovery of various new classes of RNAs and their different functions has had profound
implications for molecular biology and medical research (Figure 1). The importance of ncRNAs in
physiological and pathological processes, such as CVD, has been frequently reinforced, and they have
major regulatory roles in gene expression [6,7]. Thus, understanding the interactions between the
different types of RNA, both coding and non-coding, and how they affect gene expression in CVD,
is necessary to forward CVD management.
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In addition, knowledge of the transcriptome regulation and recent technological developments
to manipulate gene expression (e.g., RNA interference, antagomiRs, gapmers, short hairpin RNA
viral-mediated delivery of ncRNAs) allow investigation of the role and value of RNAs to personalize
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healthcare of patients affected by CVD. Thus, the transcriptome, and particularly ncRNAs, may have
a more direct application in the clinical practice. Importantly, although most ncRNAs are found inside
cells, they have been consistently identified in body fluids, including the blood [8]. The types and
amounts of different ncRNAs vary and have distinct and specific profiles in different pathophysiological
states [9,10], leading to the possibility of using these molecules as non-invasive markers of disease [11,12].
Several studies have suggested that specific ncRNA profiles may be used as diagnostic and prognostic
tools for different pathologies, including cardiovascular ones [13].
Early and accurate diagnosis and prognosis for CVD patients can optimize clinical decision making
to better adjust interventions for individual patients. Currently, optimal treatment selection and dosage
are restricted due to limited awareness of molecular and environmental information of patients [14].
A shift in medicine to focus on individuals rather than populations promises a more proactive and
predictive approach [15]. This is the concept of personalized medicine, which is committed to inspect,
diagnose, and monitor risk to ensure that patients receive treatments tailored to their molecular
and individual configuration [14]; or, if not to the individual, treatments tailored to a subgroup of
individuals that share similar traits and molecular outline [16].
However, personalized medicine presently represents a more theoretical concept than a practical
one, with the one-size-fits-all approach being still broadly used to manage CVD. To put the promise
of personalized medicine in practice, tools that stratify patients and improve healthcare need to be
accessible in the clinic, making translational research essential, meaning that basic research findings
are converted into usable applications for clinicians and patients. The basis of personalized medicine
includes targeted therapies and biomarkers, which are molecular indicators of diagnostic and prognostic
disease and treatment efficacy. The transcriptome provides an important source of therapeutic agents
and biomarkers as continually demonstrated by different research [17–19]. Although new technologies
to study the transcriptome enable information of its role in CVD mechanisms, much remains to be
elucidated as new levels of complexity are unveiled. The slow speed at which advances are occurring
in translational research suggests there are bottlenecks to be resolved [15]. Thus, there is a crucial and
urgent need for a collective effort to advance in the field by deciphering the role of the transcriptome in
CVD and create new possibilities for the development of innovative products for CVD management.
3. Objectives
This COST Action aims to accelerate the understanding of transcriptomics in CVD so personalized
medicine advances faster in this field, addressing a current public health challenge. It proposes to
constitute a network to offer opportunities for collaboration between clinicians, academic researchers
from interdisciplinary backgrounds, and industry to achieve breakthroughs and allow the transfer of
basic science into usable applications (Figure 2). CardioRNA aims to refine guidelines from the design
to the analysis of transcriptomics data to enable better comparison between studies from different
laboratories and reproducibility of results, facilitating the development of products.
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The Action will lead to creating new possibilities of basic research and product development for
personalized medicine. CardioRNA members believe that by coordinating research activities through
an interdisciplinary network, more meaningful results can be achieved. Furthermore, the platform that
will be provided by the Action will allow easier public–private partnerships to support the translation
of the new knowledge to the clinic.
Researchers from pertinent disciplines will connect through CardioRNA to organize activities to
achieve the research objectives (Table 1).
Additionally, CardioRNA will convene researchers from COST countries and International Partner
Countries (IPC) to increase scientific dialogue and provide training in the role of transcriptomics in
CVD through different types of meetings, involving students and early career investigators (ECI).
It will support them to attend meetings, training schools, and short-term scientific meetings (STSM)
within the Action.
Table 1. Research objectives of CardioRNA.
Specific Measurable Achievable Relevant Timely
Further the
understanding of the
transcriptome’s role in
CVD by establishing
a network
Number of
institutions and
investigators
joining the network
Active and increasing
collaborative research
activity in the field as
seen in the biomedical
literature
Increased knowledge on
the subject has
noteworthy implications
for the healthcare of
patients with CVD
Expansion of the
network will be
continuous
(month 1–48)
Foster collaborative
initiatives in CVD
transcriptomics
Number of Action
outputs such as
projects submitted
for funding and
scientific
publications
Collaborations will allow
optimization and
standardization of
protocols, thus helping
to deal with the
complexity of studies
Join expertise to aid
European research
groups improve and
consolidate their
research capacity and
leadership in this field
Project application to
different funding
bodies per year
(month 12–48)
Develop improved
guidelines for best
practices and
experimental standards
that offer the greatest
potential for
cardiovascular
transcriptomics studies
Production of
specific documents
(peer-reviewed
publications and
others)
Different guidelines and
techniques are
successfully used in this
field of research
Increasing
standardization will
facilitate comparison and
reproducibility of results,
allowing faster
interpretation of results
and development of new
tools to the clinic
Publish documents
on (1) best practices
on collection and
processing of
biological material
(month 24);
(2) experimental
standards for RNA
analysis in CVD
(month 40)
Stimulate development
and optimization of
RNA-based products for
prognostic, diagnostic
and therapy for CVD
management
Number of projects
that target
translational
research and
personalized
medicine
Partnerships from the
network will facilitate
study designs on the
translation of research
knowledge into
medicinal products
Regards healthcare
improvement of patients
with CVD
Projects on clinical
products
development
(month 48)
4. Progress Beyond the State-of-the-Art and Innovation Potential
The transcriptome represents all genes expressed in a tissue in a given biological state. In contrast
to DNA sequence that is constant in an individual, there is great variation in gene expression in different
tissues and different pathophysiological circumstances [20]. Specific signatures of the transcriptome
have been associated with CVD phenotypes and prognosis, while the investigation of RNA frequently
points to the structural and functional versatility of these molecules [19]. Although only less than 3%
of the human genome represent protein-coding genes, most of the genome is transcribed, leading to
the production of different types of RNA [21]. A more recent assessment of transcripts has revealed
a variety of RNA types with different sizes and shapes that do not encode proteins but have important
regulatory functions, revealing further complexity to gene expression [22]. Among these ncRNAs,
microRNAs are probably the most studied class. It is estimated that they regulate over 60% of mRNAs
in humans [23] by inhibiting their translation into proteins. Furthermore, a single microRNA can
target several mRNAs, and each mRNA can be targeted by multiple microRNAs [24]. They have also
received much attention because, unlike most RNAs, they are stable in the blood and their diversity
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and abundance may reflect distinct health states. Such characteristics make these small molecules
very good biomarker candidates for clinically relevant parameters. Besides microRNAs, there are
other types of ncRNA, including circular RNAs (also stable in the blood) and the heterogeneous class
of long non-coding RNAs (lncRNAs), playing diverse functions in the cell, possibly as cell-to-cell
communicators and with further potential as biomarkers for CVD [18,25].
Most of the available information about the transcriptome in CVD patients comes from studies
in non-cardiac tissues and cells, such as blood and blood cells, mainly due to their accessibility [26].
Nonetheless, particularly ncRNAs have been associated with nearly all cardiovascular processes,
from normal heart development to stress response in adults, regulating heart hypertrophy, contractility,
fibrosis, apoptosis, and gene expression. They also modulate gene expression and cell fate in vascular
endothelial and mural (smooth muscle cells and pericytes) cells, playing a role in vascular biology [27,28].
Still, there is much to explore and learn about the biological mechanisms of ncRNAs contributing
to homeostasis and CVD, a task that may be complicated partly due to their diverse mechanisms of
action [25]. This hampers the exploitation of the full potential of RNA-based therapeutics. Since ncRNAs
are important regulators of pathophysiological processes in the cardiovascular system and are present
in the blood in protected forms that prevent their degradation, they have potential to be used as
diagnostic and prognostic markers and as therapeutic targets [18,25,29].
High-throughput sequencing technologies combined with bioinformatics and computational
biology have recently helped expand the field of transcriptomics [30]. Three main techniques
are diffusely employed to assess RNA expression: RNA sequencing (RNA-seq), microarrays,
and quantitative real-time polymerase chain reaction (qPCR). The first is used to obtain a complete
profile of RNA in a sample, while the others are used to detect previously characterized RNAs [31].
All techniques have been widely used to enlighten our understanding of the transcriptome. However,
the field is still in its infancy and faces many challenges. First is the complexity of the whole
transcriptome due to its various players, their interactions, and different mechanisms of action.
These relationships and functions are still to be determined. Another issue is the lack of consensus on
all steps of the process on how to best perform and interpret experiments of CVD transcriptomic studies.
Comparison of results and replication of experiments are imperative to advance in gene expression
studies. For example, the quality of RNA is crucial to obtain reliable results [26], especially because
RNA profiles can be easily disturbed by sample collection and processing [32]. For microRNA studies,
in particular, different sample types (e.g., serum, plasma, blood collection in heparin) and measurement
platforms can affect the microRNA quantification results [33]. Moreover, there is an urgent need to
develop internal and better external reference materials for such studies.
Thus, transcriptomics holds potential to explain fundamental biological phenomena in the
developing field of ncRNAs within a CVD context and to advance medicine through the development
of new diagnostic and therapeutic tools. However, for transcriptomics to fulfill the promise of
improving healthcare, technical advances and a better understanding of the biological functions of
ncRNA must be accomplished. This Action aims to both refine and standardize RNA analyses and
reveal ncRNA molecules that might be useful to detect disease, predict its progression, and treat it.
CardioRNA believes the critical challenges regarding transcriptomics studies in CVD can be
significantly mitigated by coordinating efforts from different groups through this Action, leading to
progress in the quality and speed of findings in the field and, hence, in healthcare. The topics to be
tackled in this Action all contribute to such advancement, and networking will allow researchers to
identify and come up with innovative ways to answer difficult biological questions regarding the role
of RNA in CVD.
The organisation of events and meetings during this Action will pave the way for discussions
and knowledge exchange about RNA interactions that may prevent or lead to CVD, identify gaps in
the current transcriptomics in CVD research, and define future directions of study, all adding to the
current state-of-the-art. The Action will support the continuity of studies and projects focusing on
basic and translational research. By targeting best practices on every step along a transcriptomics CVD
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study pipeline, the Action aims to increase comparison and reproducibility of results between different
laboratories that will interest investigators beyond CardioRNA members. Among the current partners
are experts on clinical biobanking and biospecimen science who can provide a valuable contribution
to best practices for CVD sample collection and processing and aid in the production of guidelines
to build reference materials for CVD, for instance. Furthermore, the elaboration of an inventory of
available patient cohorts classified by main CVD will substantially help researchers find adequate
cohorts for their studies and may facilitate collaborations.
The immediate benefits of this Action will be the advancement of scientific collaboration across
Europe and the unification of transcriptomics research in CVD through the network, involving clinical,
academic, and industrial partners.
5. Added Value of Networking
The potential applications of transcriptomics to aid manage CVD are clear; however, knowledge of
its role in this context is still coming to light, especially as technologies progress and novel players and
interactions emerge, together with new possibilities. A broader coordinated structure can significantly
enhance existing collaborations between groups. This COST Action is well-suited for strengthening
ongoing collaborations and establishing new ones by the creation of a large, interdisciplinary,
and international network to jointly orchestrate and strategically plan integrated activities that
will result in meaningful advancements in the field and, eventually, in healthcare. To maximize the
potential of European research in the important and still developing field of transcriptomics and speed
up breakthroughs, coordination of efforts is paramount to make a greater impact.
Networking through this Action will allow, not only the initiation of important discussions about
the transcriptome’s role in CVD, but also allow us to search, identify, and define new directions of study
and plan future projects benefiting from the expertise of members from different disciplines. Also,
networking is key to deal with the current lack of consensus for best practices in transcriptomics studies
for CVD, which hinders the development of RNA-based products particularly. Appropriate procedures
and standards throughout the entire process to generate data from RNA are key to determine the
quality of information and its later applications. Thus, an organized network with a dedicated working
group (WG) focusing on best practices will facilitate the establishment, acceptance, and dissemination
of standard practices due to a large number of participants and their widespread locations, extending
to their networks worldwide.
6. Expected Impact
CardioRNA expects widespread coordination of various parties interested in the context of
transcriptomics in CVD. It anticipates exchange among the members and knowledge transfer to
students and young researchers. Consequently, this Action will provide the basis for significant
advancements for CVD transcriptomics and translational research as well as personalized medicine,
impacting society in addition to the scientific community.
In the short term, this Action will have the following scientific, technological, and socioeconomic
impacts:
1. Research collaboration and joint grant applications for future national and European funding;
2. Increase the competitiveness of the network participants for European funding and the impact of
resulting research;
3. Encourage translational research due to the participation of industrial partners in the network;
4. Stimulate innovative perspectives to study the transcriptome due to CardioRNA’s
multidisciplinary team;
5. Provide opportunities and scientific training for ECI and students through workshops, training
schools, and STSMs.
The long-term impacts of the Action include:
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1. Expand fundamental knowledge about the role of the transcriptome in CVD to improve its
prognostics, diagnostics, and treatment;
2. Increase the quality of data generated and reproducibility of studies of the CVD transcriptome,
thus raising the quality and impact of publications;
3. Establish a leadership of both the network members and the European research axis in the
proposed research field;
4. Foster personalized medicine and consequently healthcare, through outcomes of public–private
collaborations.
7. Potential for Innovation
The main potential innovations from this Action will be the result of increasing collaboration
through a coordinated initiative to optimize returns on scientific investment, filling the gap of unmet
knowledge and clinical needs in CVD personalized medicine. Thus, the Action will have two main
potential impacts: A scientific and technological one and a socioeconomic one. From the scientific and
technological point of view, the combination of expertise from the participating research groups at the
front line of transcriptomics in CVD will lead to significant breakthroughs in the knowledge level in this
field and potentially to novel intellectual property for clinical applications. This, in turn, will positively
impact healthcare. However, to be successful in understanding transcriptomics in CVD and fulfilling its
innovation potential as biomarkers and therapeutic targets, standardization of best practices is urgent.
This topic will be addressed by WG2, which will devise strategies to minimize low reproducibility
of experiments, diversity of sample types, and their collection and processing. Harmonization of
procedures is a prerequisite to reproducibility and further industrial developments of translational
research findings. Many new therapeutic or biomarker candidates fail to be reproduced/validated
due to unstandardized methodologies for blood collection, marker assessment, or even inadequate
statistical analyses. CardioRNA will provide new lines of conduct to reduce the rate of failure to
validate new findings from research laboratories, increasing the chances of bringing to commercial
application novel RNA targets. To minimize the risk associated with harmonization of procedures,
the consortium gathers experts in biobanking, biospecimen science, and bioinformatics, fields that
cover topics necessary for procedures’ standardization. Discussions and exchange of experiences
within these experts will reduce the risk of failure to provide new standardization guidelines to
an acceptable level. Such an endeavor can only be achieved through the cooperation and coordination
of research groups active in the field, which this Action will promote.
CardioRNA will also boost the success chances of personalized medicine endeavors, which require
know-how from industry. The network’s industry partners are small and medium enterprise (SME)
leaders in technology and experienced in developing biomarkers into diagnostic tools, discovering
and designing drugs, and introducing technologies and devices into laboratories worldwide. Thus,
this Action can also contribute to socioeconomic innovation by accelerating the development of products
for the clinic, allowing doctors to better tailor treatment to the needs of each patient. For example,
in some cases, a standard treatment is administered to every patient because there are no tools to
stratify specific groups at risk, leading to increased patient burden due to unnecessary treatment and
excessive healthcare costs. Additionally, RNA-based therapy potentially represents a powerful tool for
personalized medicine due to their specific expression patterns associated with distinct pathologies.
But for being in its early days, it faces challenges related to scientific and business aspects. CardioRNA
plans to deal with these risks by building an interdisciplinary network to be able to have a systems
approach to the complexity of the transcriptome and CVD and the population variability. Hence,
we expect to give the CVD community successful case studies that can inspire and orient future efforts
for therapy development.
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8. Implementation Plan
CardioRNA will be organized into four interrelated working groups (WG) to optimize the
accomplishment of the main proposed goals (Figure 3). Three WGs will be dedicated to developing
science-related activities and meet the research coordination goals. One WG will communicate within
and outside the network and support the other WGs to develop their networking activities.
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8.1. WG1: Regulatory Function of the Transcripto e
The human transcriptome is composed of coding and non-coding transcripts. Among the
non-coding transcripts, one distinguishes short ncRNAs and lncRNAs. The latter group is the largest
and most diverse class of transcripts and exerts regulatory functions that ultimately control cell
identity and behavior. In particular, this regulatory layer integrates developmental and environmental
cues to shape the various cellular responses implicated in development and disease. Although
microRNAs have been extensively studie in the context of cardiovascular disease, lncRNAs need
to be syste atically investigated. A b tter un erstan ing of their importance as regulators of
the gene programs controlling the respons t stress should allow identification of new targets
for improving diagnosis and treatment. WG1 will, therefore, focus on identifying novel ncRNAs
and characterizing their regulatory functions in cardiovascular pathophysiology, including their
interactions with protein-coding transcripts. One aspect that will be addressed is the difference of
ncRNA expression according to gender. This WG will provide training in the various approaches and
techniques that are used to probe and manipulate the transcriptome to study the role of ncRNAs in the
cardiovascular system.
8.2. WG2: Best Practices and Experimental Standards
Comparison of pr tocols and data fr m different lab ratories is necessary to facilitate the
comprehension of results and adva ce knowledge in CVD transcriptomics. It also directly impacts
the development of tools that can be used for diagnosis and monitoring of CVD. To compare results,
generated data must meet common standards, which should be from the collection of samples to
the generation and analysis of data, so that variations are minimized and results are accurate and
reproducible. Sample collection, storage, and quality testing are critical, particularly when dealing
with RNA due to its sensitive nature. Although guidelines exist for separate steps of sample collection,
data generation, and analysis, a complete guideline comprising all steps that are specific for CVD is still
lacking. WG2 will focus on the best practices for cardiovascular transcriptomic studies from the crucial
issue of sample coll cti n and processing, which directly i cts fin l results, o the main techniques
used to study the transcriptome (qPCR, microarray, and RNA sequencing) and the statistical analysis.
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Protocols, technologies, and procedures will be assessed, and standard strategies will be delineated for
better quality control and study comparison, tackling all the steps along the process. This Action aims
to bring together in WG2 experts from relevant disciplines to discuss and come up with guidelines to
generate reference materials for CVD and also for the production of internal quality control materials
that can be used in CVD transcriptome analyses.
8.3. WG3: Development of Cohort Inventory
The main goal of WG3 is to create an inventory of cohorts from healthy individuals and CVD
patients to provide awareness of the available cohorts that can be used in research, thus, facilitating
collaborations. Such an inventory, with key characteristics of the cohort (paying particular attention to
gender) and information on the principal investigator, will be made available to the public through this
COST Action’s website and possibly through websites from other relevant organizations and institutions
(e.g., Biobanking and BioMolecular Resources Research Infrastructure Directory, International Society
for Biological and Environmental Repositories).
8.4. WG4: Dissemination
WG4 will be responsible for promoting communication, knowledge exchange, and bringing new
members to the network. This WG will organize yearly CardioRNA network meetings and provide
support for the different WGs to organize their meetings, workshops, STSMs, and training schools.
It will also be responsible for providing updates on the activities of the network and disseminating the
Action’s progress and initiatives to the public.
9. Concluding Remarks
In summary, our COST Action aims to help alleviate the global burden of CVD by addressing
the following challenges: Increase the knowledge of the role played by the complex transcriptome in
CVD by coordinating efforts from different groups; refine common standards and best practices that
will offer the greatest potential for transcriptome studies in CVD as well as increase reproducibility
between studies and advance product development; and assure continuity of studies focusing on
translational research and public–private partnerships to enhance personalized medicine.
Represented by scientists with multidisciplinary backgrounds and SMEs distributed throughout
Europe and beyond, this Action’s initiatives will potentially expand within the participants existing
collaboration networks. Both the main subject of CardioRNA and the lack of coordination of efforts to
deal with it are widespread, making cooperation beneficial.
Funding: This work is supported by COST (European Cooperation in Science and Technology) Action
EU-CardioRNA CA17129. YD is the chair and CE is the vice-chair of the European COST Action
CA17129, CardioRNA.
Conflicts of Interest: The authors declare no conflict of interest. The funders have no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
References
1. Mendis, S.; Puska, P.; Norrving, B.; World Health Organization; World Heart Federation; World Stroke
Organization. Global Atlas on Cardiovascular Disease Prevention and Control; World Health Organization in
collaboration with the World Heart Federation and the World Stroke Organization: Geneva, Switzerland,
2011; p. vi. 155p.
2. Wilkins, E.; Wilson, L.; Wickramasinghe, K.; Bhatnagar, P.; Leal, J.; Luengo-Fernandez, R.; Burns, R.;
Rayner, M.; Townsend, N. European Cardiovascular Disease Statistics 2017; European Heart Network: Brussels,
Belgium; European Society of Cardiology: Sophia Antipolis, France, 2017.
3. Medicine, I.O. Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global
Health; The National Academies Press: Washington, DC, USA, 2010; p. 482. [CrossRef]
Non-coding RNA 2019, 5, 31 12 of 13
4. Booth, F.W.; Gordon, S.E.; Carlson, C.J.; Hamilton, M.T. Waging war on modern chronic diseases: Primary
prevention through exercise biology. J. Appl. Physiol. 2000, 88, 774–787. [CrossRef]
5. Kearney, P.M.; Whelton, M.; Reynolds, K.; Muntner, P.; Whelton, P.K.; He, J. Global burden of hypertension:
Analysis of worldwide data. Lancet 2005, 365, 217–223. [CrossRef]
6. Jacquier, A. The complex eukaryotic transcriptome: unexpected pervasive transcription and novel small
RNAs. Nat. Rev. Genet. 2009, 10, 833–844. [CrossRef] [PubMed]
7. Papageorgiou, N.; Tslamandris, S.; Giolis, A.; Tousoulis, D. MicroRNAs in Cardiovascular Disease:
Perspectives and Reality. Cardiol. Rev. 2016, 24, 110–118. [CrossRef]
8. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.;
Noteboom, J.; O’Briant, K.C.; Allen, A.; et al. Circulating microRNAs as stable blood-based markers for
cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513–10518. [CrossRef] [PubMed]
9. Arroyo, J.D.; Chevillet, J.R.; Kroh, E.M.; Ruf, I.K.; Pritchard, C.C.; Gibson, D.F.; Mitchell, P.S.; Bennett, C.F.;
Pogosova-Agadjanyan, E.L.; Stirewalt, D.L.; et al. Argonaute2 complexes carry a population of circulating
microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. USA 2011, 108, 5003–5008.
[CrossRef] [PubMed]
10. Weber, J.A.; Baxter, D.H.; Zhang, S.; Huang, D.Y.; Huang, K.H.; Lee, M.J.; Galas, D.J.; Wang, K. The microRNA
spectrum in 12 body fluids. Clin. Chem. 2010, 56, 1733–1741. [CrossRef]
11. Cortez, M.A.; Bueso-Ramos, C.; Ferdin, J.; Lopez-Berestein, G.; Sood, A.K.; Calin, G.A. MicroRNAs in body
fluids—The mix of hormones and biomarkers. Nat. Rev. Clin. Oncol. 2011, 8, 467–477. [CrossRef]
12. Devaux, Y. Transcriptome of blood cells as a reservoir of cardiovascular biomarkers. Biochim. Biophys. Acta
Mol. Cell Res. 2017, 1864, 209–216. [CrossRef]
13. Goretti, E.; Wagner, D.R.; Devaux, Y. miRNAs as biomarkers of myocardial infarction: A step forward
towards personalized medicine? Trends Mol. Med. 2014, 20, 716–725. [CrossRef] [PubMed]
14. Antman, E.M.; Loscalzo, J. Precision medicine in cardiology. Nat. Rev. Cardiol. 2016, 13, 591–602. [CrossRef]
[PubMed]
15. Duffy, D.J. Problems, challenges and promises: Perspectives on precision medicine. Brief. Bioinform. 2016, 17,
494–504. [CrossRef] [PubMed]
16. Hall, M.A.; Moore, J.H.; Ritchie, M.D. Embracing Complex Associations in Common Traits: Critical
Considerations for Precision Medicine. Trends Genet. 2016, 32, 470–484. [CrossRef] [PubMed]
17. Byron, S.A.; Van Keuren-Jensen, K.R.; Engelthaler, D.M.; Carpten, J.D.; Craig, D.W. Translating RNA
sequencing into clinical diagnostics: Opportunities and challenges. Nat. Rev. Genet. 2016, 17, 257–271.
[CrossRef] [PubMed]
18. Devaux, Y.; Zangrando, J.; Schroen, B.; Creemers, E.E.; Pedrazzini, T.; Chang, C.P.; Dorn, G.W., 2nd; Thum, T.;
Heymans, S.; Cardiolinc, N. Long noncoding RNAs in cardiac development and ageing. Nat. Rev. Cardiol.
2015, 12, 415–425. [CrossRef] [PubMed]
19. Sullenger, B.A.; Nair, S. From the RNA world to the clinic. Science 2016, 352, 1417–1420. [CrossRef]
20. Pedrotty, D.M.; Morley, M.P.; Cappola, T.P. Transcriptomic biomarkers of cardiovascular disease. Prog.
Cardiovasc. Dis. 2012, 55, 64–69. [CrossRef] [PubMed]
21. Consortium, E.P. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489,
57–74. [CrossRef] [PubMed]
22. Filipowicz, W.; Bhattacharyya, S.N.; Sonenberg, N. Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat. Rev. Genet. 2008, 9, 102–114. [CrossRef] [PubMed]
23. Friedman, R.C.; Farh, K.K.; Burge, C.B.; Bartel, D.P. Most mammalian mRNAs are conserved targets of
microRNAs. Genome Res. 2009, 19, 92–105. [CrossRef] [PubMed]
24. Lewis, B.P.; Burge, C.B.; Bartel, D.P. Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that
Thousands of Human Genes are MicroRNA Targets. Cell 2005, 120, 15–20. [CrossRef]
25. Boon, R.A.; Jae, N.; Holdt, L.; Dimmeler, S. Long Noncoding RNAs: From Clinical Genetics to Therapeutic
Targets? J. Am. Coll. Cardiol. 2016, 67, 1214–1226. [CrossRef] [PubMed]
26. Schnabel, R.B.; Baccarelli, A.; Lin, H.; Ellinor, P.T.; Benjamin, E.J. Next steps in cardiovascular disease genomic
research–sequencing, epigenetics, and transcriptomics. Clin. Chem. 2012, 58, 113–126. [CrossRef] [PubMed]
27. Gurha, P.; Marian, A.J. Noncoding RNAs in cardiovascular biology and disease. Circ. Res. 2013, 113,
e115–e120. [CrossRef] [PubMed]
Non-coding RNA 2019, 5, 31 13 of 13
28. Philippen, L.E.; Dirkx, E.; da Costa-Martins, P.A.; De Windt, L.J. Non-coding RNA in control of gene
regulatory programs in cardiac development and disease. J. Mol. Cell Cardiol. 2015, 89, 51–58. [CrossRef]
[PubMed]
29. Ong, S.B.; Katwadi, K.; Kwek, X.Y.; Ismail, N.I.; Chinda, K.; Ong, S.G.; Hausenloy, D.J. Non-coding RNAs as
therapeutic targets for preventing myocardial ischemia-reperfusion injury. Expert Opin. Therap. Targets 2018,
22, 247–261. [CrossRef] [PubMed]
30. Ozsolak, F.; Milos, P.M. RNA sequencing: advances, challenges and opportunities. Nat. Rev. Genet. 2011, 12,
87–98. [CrossRef] [PubMed]
31. Pritchard, C.C.; Cheng, H.H.; Tewari, M. MicroRNA profiling: Approaches and considerations. Nat. Rev.
Genet. 2012, 13, 358–369. [CrossRef]
32. Bustin, S.A.; Benes, V.; Garson, J.A.; Hellemans, J.; Huggett, J.; Kubista, M.; Mueller, R.; Nolan, T.; Pfaffl, M.W.;
Shipley, G.L.; et al. The MIQE guidelines: Minimum information for publication of quantitative real-time
PCR experiments. Clin. Chem. 2009, 55, 611–622. [CrossRef]
33. Wang, K.; Yuan, Y.; Cho, J.H.; McClarty, S.; Baxter, D.; Galas, D.J. Comparing the MicroRNA spectrum
between serum and plasma. PLoS ONE 2012, 7, e41561. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
